PROJECT NUMBER

23045

Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for Plasmodium vivax

Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for *Plasmodium vivax.*

Applications: Synthetic polypeptide, vaccination against Plasmodium vivax



Features	Benefits
Novel immunogen based on modified Duffy binding domain (DBP) of Plasmodium vivax, specifically subdomain 3 of the PvDBP-RII protein domain	Effectively target the reticulocyte invasion stage of Plasmodium vivax to prevent symptoms and malaria transmission
Structure-guided immunogen design, which modifications allows production of correctly folded form	Modifications leading to immunogen allows effective production and scalability, hence effective vaccination
Preclinical data demonstrates a more effective growth-inhibitory antibody repertoire compared to the current best PvDBP-RII immunogen	Ready to be tested in clinical trials
Immunogen can be included in prophylaxis for Malaria by itself or in combination with other components as a multi-stage vaccine	Can be used for analysing antibody repertoire generated in response to vaccination or natural infection

Features	Benefits
	Adaptability in vaccine program design

Awaiting patent and Available for

- Co-development
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.